Korean J Gastroenterol.  2020 Dec;76(6):297-303. 10.4166/kjg.2020.098.

Clinical Outcomes of Mucinous Gastric Carcinomas Compared with Non-mucinous and Signet Ring Cell Carcinomas

• Ahn H
• Chung WC
• Kim YJ
• Ryu S
• Lim E

• KMID: 2509706
• DOI: http://doi.org/10.4166/kjg.2020.098

Abstract

Background/Aims
This study examined the clinical features and prognosis of patients with mucinous gastric carcinoma (MGC), non-mucinous gastric carcinoma (NMGC), and signet ring cell gastric carcinoma (SRC).
Methods
A retrospective cohort study was performed, enrolling 65 patients with MGC from January 2007 to December 2016. During the same period, 1,814 patients with histologically proven gastric cancers underwent curative or palliative operations. One hundred and ninety-five NMGC patients were selected as the 1:3 age- and sex-matched control groups. In addition, 200 SRC patients were identified. This study evaluated the demographic features of the patients, pathologic features of the tumor, and the predictive factors, such as the recurrence-free survival and overall survival.
Results
The recurrence rates were significantly high in MGC than in NMGC or SRC (both p<0.01). The proportion of early gastric cancer was lower in the MGC group than in the other groups (p<0.01). In addition, metastatic lymph nodes were found more frequently in the MGC group (p<0.01), and the proportion of initial pT4, M1 stage, was highest in the MGC group. The recurrence-free survival and overall survival in the MGC group were significantly lower than those in the NMGC or SRC. Subgroup analysis showed that patients with the same American Joint Committee on Cancer (AJCC) stage of each cancer group showed a similar prognosis.
Conclusions
MGC frequently presents an advanced stage with an unfavorable prognosis compared to NMGC or SRC. On the other hand, MGC of the same AJCC stage had a similar prognosis to NMGC and SRC.

Keyword

Stomach neoplasms; Mucins; Prognosis

Figure

• 

  Fig. 1 Flow diagram showing patient selection for this study.

• 

  Fig. 2 Kaplan-Meier curves of the recurrence-free survival of MGC, NMGC, and SRC groups. MGC, mucinous gastric carcinoma; NMGC, non-mucinous gastric carcinoma; SRC, signet ring cell carcinoma.

• 

  Fig. 3 Kaplan-Meier curves of the overall survival of MGC, NMGC, and SRC groups. MGC, mucinous gastric carcinoma; NMGC, non-mucinous gastric carcinoma; SRC, signet ring cell carcinoma.

• 

  Fig. 4 Kaplan-Meier curves of recurrence-free survival of MGC, NMGC, and SRC groups at each AJCC stage. MGC, mucinous gastric carcinoma; NMGC, non-mucinous gastric carcinoma; SRC, signet ring cell carcinoma; AJCC, American Joint Commettee on Cancer.

• 

  Fig. 5 Kaplan-Meier curves of the overall survival of MGC, NMGC, and SRC groups at each AJCC stage. MGC, mucinous gastric carcinoma; NMGC, non-mucinous gastric carcinoma; SRC, signet ring cell carcinoma; AJCC, American Joint Commettee on Cancer.

Reference

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. DOI: 10.3322/caac.21492. PMID: 30207593.

2. Kunisaki C, Akiyama H, Nomura M, et al. 2006; Clinicopathologic characteristics and surgical outcomes of mucinous gastriccarcinoma. Ann Surg Oncol. 13:836–842. DOI: 10.1245/ASO.2006.03.077. PMID: 16604474.

3. Zhang M, Zhu GY, Zhang HF, Gao HY, Han XF, Xue YW. 2010; Clinicopathologic characteristics and prognosis of mucinous gastric carcinoma. J Surg Oncol. 102:64–67. DOI: 10.1002/jso.21533. PMID: 20578080.

4. Zhang M, Zhu G, Zhang H, Gao H, Xue Y. 2010; Clinicopathologic features of gastric carcinoma with signet ring cell histology. JGastrointest Surg. 14:601–606. DOI: 10.1007/s11605-009-1127-9. PMID: 20033340.

5. Kwon KJ, Shim KN, Song EM, et al. 2014; Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Gastric Cancer. 17:43–53. DOI: 10.1007/s10120-013-0234-1. PMID: 23389081.

6. Choi JS, Kim MA, Lee HE, Lee HS, Kim WH. 2009; Mucinous gastric carcinomas: clinicopathologic and molecular analyses. Cancer. 115:3581–3590. DOI: 10.1002/cncr.24422. PMID: 19479974.

7. Jian-Hui C, Shi-Rong C, Hui W, et al. 2016; Gastric mucinous cancer histology: clinicopathological characteristics and prognostic value. Gastroenterol Res Pract. 2016:8947505. DOI: 10.1155/2016/8947505. PMID: 26839544. PMCID: PMC4709619.

8. Jiang H, Zhang H, Tian L, Zhang X, Xue Y. 2013; The difference in clinic-pathological features between signet ring cell carcinoma and gastric mucinous adenocarcinoma. Tumour Biol. 34:2625–2631. DOI: 10.1007/s13277-013-0812-1. PMID: 23636798.

9. Bu Z, Zheng Z, Li Z, et al. 2013; Clinicopathological and prognostic differences between mucinous gastric carcinoma and signet-ringcell carcinoma. Chin J Cancer Res. 25:32–38.

10. Kawamura H, Kondo Y, Osawa S, et al. 2001; A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 4:83–86. DOI: 10.1007/PL00011728. PMID: 11706765.

11. Lim SW, Kim DY, Kim YJ, Kim SK. 2002; Clinicopathologic features ofmucinous gastric carcinoma. Dig Surg. 19:286–290. DOI: 10.1159/000064583. PMID: 12207072.

12. Adachi Y, Mori M, Kido A, Shimono R, Maehara Y, Sugimachi K. 1992; A clinicopathologic study of mucinous gastric carcinoma. Cancer. 69:866–871. DOI: 10.1002/1097-0142(19920215)69:4<866::AID-CNCR2820690405>3.0.CO;2-D.

13. Yasuda K, Shiraishi N, Inomata M, Shiroshita H, Ishikawa K, Kitano S. 2004; Clinicopathologic characteristics of early-stage mucinous gastric carcinoma. J Clin Gastroenterol. 38:507–511. DOI: 10.1097/01.mcg.0000128991.59549.9a. PMID: 15220686.

14. Ryu SY, Kim HG, Lee JH, Kim DY. 2014; Prognosis of early mucinous gastric carcinoma. Ann Surg Treat Res. 87:5–8. DOI: 10.4174/astr.2014.87.1.5. PMID: 25025020. PMCID: PMC4091442.

15. Ajani JA IH, Sano T, Gaspar LE, et al. Amin MB, Greene FL, Edge SB, editors. 2017. Stomach. AJCC cancer staging manual. 8th ed. Springer;New York: p. 203–220. DOI: 10.1007/978-3-319-40618-3_17.

16. Isobe T, Hashimoto K, Kizaki J, et al. 2015; Characteristics and prognosis of mucinous gastric carcinoma. Mol Clin Oncol. 3:44–50. DOI: 10.3892/mco.2014.447. PMID: 25469268. PMCID: PMC4251105.

17. Yuan Y, Chen Z, Chen J, et al. 2018; Mucinous gastric carcinoma: an update of clinicopathologic features and prognostic value from aretrospective study of clinical series. Int J Clin Exp Pathol. 11:813–821.

18. Shin SH, Bae JM, Jung H, et al. 2010; Clinical significance of the discrepancy between preoperative and postoperative diagnoses in gastric cancer patients. J Surg Oncol. 101:384–388. DOI: 10.1002/jso.21500. PMID: 20127892.

19. Yu BC, Lee WK. 2013; Two cases of mucinous adenocarcinoma of the stomach mistaken as submucosal tumor. J Korean Surg Soc. 84:118–122. DOI: 10.4174/jkss.2013.84.2.118. PMID: 23396274. PMCID: PMC3566470.

20. Hyung WJ, Noh SH, Shin DW, et al. 1999; Clinicopathologic characteristics of mucinous gastric adenocarcinoma. Yonsei Med J. 40:99–106. DOI: 10.3349/ymj.1999.40.2.99. PMID: 10333711.

21. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. 2015; Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 21:11428–11438. DOI: 10.3748/wjg.v21.i40.11428. PMID: 26523107. PMCID: PMC4616218.

22. Chon HJ, Hyung WJ, Kim C, et al. 2017; Differential prognostic implications of gastric signet ring cell carcinoma: stage adjustedanalysis from a single high-volume center in Asia. Ann Surg. 265:946–953. DOI: 10.1097/SLA.0000000000001793. PMID: 27232252. PMCID: PMC5389602.